Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
TrivarX Limited ( (AU:TRI) ) just unveiled an announcement.
TrivarX Limited announced positive engagement with the US FDA regarding its MEB-001 algorithm, designed for screening major depressive episodes through data from in-clinic sleep studies. This validation boosts confidence in their pivotal trial design, which is essential for FDA approval. The trial aims to recruit 563 patients across multiple US sites and compares MEB-001 against a gold standard diagnosis method. This development is expected to enhance TrivarX’s position in the mental health screening industry and unlock collaborations with prominent hospitals, potentially benefiting stakeholders through access to high-volume patient locations.
More about TrivarX Limited
TrivarX Limited is a mental health technology company focused on developing objective measures for early detection and screening of mental health conditions. Based in Perth, Australia, and Minneapolis, USA, the company is publicly traded on the Australian Securities Exchange and the OTCQB Venture Market.
YTD Price Performance: 0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.99M
See more insights into TRI stock on TipRanks’ Stock Analysis page.
